Milan, Italy – April 6, 2010 - Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announces that at its Ordinary and Extraordinary General Meetings held in Bresso/Milan on April 2, 2010 all motions proposed by the Board of Directors were approved. The mandate for the accounting control and external auditing for certification relating to the financial years 2010, 2011 and 2012 was granted to Reconta Ernst & Young S.p.A. The three permanent members of the Board of Statutory Auditors were confirmed for another 3-year-mandate, as well.
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide for the treatment of Parkinson’s disease (PD) in conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer’s disease, and other therapeutic applications. Newron is in the process of completing a potentially pivotal study (SERENA) with ralfinamide in patients with Neuropathic Low Back Pain (NLBP). Newron’s additional projects are in development at various stages of preclinical and clinical development, including HF0220 for neuroprotection and NW-3509 for the treatment of schizophrenia. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SIX Swiss Exchange, trading symbol NWRN.
